Rasna Therapeutics Stock Probability of Future Pink Sheet Price Finishing Under 0.0249

RASP Stock  USD 0  0.00  0.00%   
Rasna Therapeutics' future price is the expected price of Rasna Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Rasna Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Rasna Therapeutics Backtesting, Rasna Therapeutics Valuation, Rasna Therapeutics Correlation, Rasna Therapeutics Hype Analysis, Rasna Therapeutics Volatility, Rasna Therapeutics History as well as Rasna Therapeutics Performance.
  
Please specify Rasna Therapeutics' target price for which you would like Rasna Therapeutics odds to be computed.

Rasna Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Rasna Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Rasna Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Rasna Therapeutics generated a negative expected return over the last 90 days
Rasna Therapeutics has some characteristics of a very speculative penny stock
Rasna Therapeutics currently holds 91.97 K in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the company is not taking enough advantage from borrowing. Rasna Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Rasna Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Rasna Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rasna Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rasna to invest in growth at high rates of return. When we think about Rasna Therapeutics' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (686.59 K) with profit before overhead, payroll, taxes, and interest of 0.
Rasna Therapeutics currently holds about 10.52 K in cash with (312.66 K) of positive cash flow from operations.
Roughly 85.0% of Rasna Therapeutics outstanding shares are owned by corporate insiders

Rasna Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Rasna Pink Sheet often depends not only on the future outlook of the current and potential Rasna Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Rasna Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding111.4 M
Cash And Short Term Investments39.4 K

Rasna Therapeutics Technical Analysis

Rasna Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Rasna Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Rasna Therapeutics. In general, you should focus on analyzing Rasna Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.

Rasna Therapeutics Predictive Forecast Models

Rasna Therapeutics' time-series forecasting models is one of many Rasna Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Rasna Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.

Things to note about Rasna Therapeutics

Checking the ongoing alerts about Rasna Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Rasna Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Rasna Therapeutics generated a negative expected return over the last 90 days
Rasna Therapeutics has some characteristics of a very speculative penny stock
Rasna Therapeutics currently holds 91.97 K in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the company is not taking enough advantage from borrowing. Rasna Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Rasna Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Rasna Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rasna Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rasna to invest in growth at high rates of return. When we think about Rasna Therapeutics' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (686.59 K) with profit before overhead, payroll, taxes, and interest of 0.
Rasna Therapeutics currently holds about 10.52 K in cash with (312.66 K) of positive cash flow from operations.
Roughly 85.0% of Rasna Therapeutics outstanding shares are owned by corporate insiders

Additional Tools for Rasna Pink Sheet Analysis

When running Rasna Therapeutics' price analysis, check to measure Rasna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rasna Therapeutics is operating at the current time. Most of Rasna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rasna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rasna Therapeutics' price. Additionally, you may evaluate how the addition of Rasna Therapeutics to your portfolios can decrease your overall portfolio volatility.